Cocrystal Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $5.1M | $12.5M | $15.2M | $12.4M | $8.8M |
| Operating expenses | $9.0M | $17.9M | $18.6M | $38.8M | $14.2M |
| Operating income | -$9.0M | -$17.9M | -$18.6M | -$38.8M | -$14.2M |
| Interest expense | $134,000 | $537,000 | $640,000 | $2,000 | $4,000 |
| Pretax income | -$8.8M | -$18.6M | — | — | — |
| Net income | -$8.8M | -$17.5M | -$18.0M | -$38.8M | -$14.2M |
| Balance Sheet | |||||
| Cash and equivalents | $7.0M | $9.9M | $26.4M | $37.1M | $58.7M |
| Current assets | $8.1M | $11.6M | $29.1M | $40.2M | $59.3M |
| Total assets | $9.7M | $13.5M | $31.3M | $40.8M | $79.4M |
| Current liabilities | $2.2M | $2.4M | $3.3M | $1.2M | $1.5M |
| Total liabilities | $3.4M | $3.9M | $4.9M | $1.3M | $1.8M |
| Stockholders' equity | $6.3M | $9.5M | $26.4M | $39.6M | $77.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$8.2M | -$16.5M | -$14.7M | -$21.4M | -$12.7M |
| Depreciation and amortization | $72,000 | $126,000 | $189,000 | $185,000 | $190,000 |
| Stock-based compensation | $270,000 | $643,000 | $801,000 | $855,000 | $724,000 |
| Capital expenditure | $12,000 | $8,000 | $118,000 | $74,000 | $52,000 |
| Free cash flow | -$8.2M | -$16.5M | -$14.8M | -$21.5M | -$12.8M |
| Impairments | — | — | — | $19.1M | — |
Shares outstanding 13.8M
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.